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Focal glomeruloscierosis in idiopathic membranous glomerulonephri-
tis. The significance of the finding of focal glomerulosclerosis (FGS) in
idiopathic membranous glomerulonephritis (MGN) is uncertain. Twen-
ty-seven patients with mixed FGS and MGN (MGN-FGS) were com-
pared to 25 patients with MGN alone (generally matched for age, sex
and stage of glomerular lesion) with respect to pathology, presenting
clinical and laboratory features, and course of disease. Biopsies from
the MGN-FGS patients showed significantly more extensive tubuloin-
terstitial disease (P < 0.001) than did those with MON alone. At the
time of biopsy, the MGN-FGS group had a significantly higher propor-
tion of patients with hypertension (P = 0.006) and microhematuria (P =
0.006), a marginally higher percentage of patients with the nephrotic
syndrome (P = 0.051), and a greater mean 24-hour urinary protein
excretion (P = 0.004). A similar proportion of patients in each group
were treated with either prednisone alone or prednisone with an
immunosuppressive. Forty-eight percent of MGN-FGS patients and
13% of the MGN patients developed established renal failure in the
follow-up period (P = 0.008). The renal survival rate for the MGN-FGS
group was significantly lower at 24 months (0.61 vs. 0.93, P < 0.05), 60
months (0.48 vs. 0.88, P < 0.025), and over the entire follow-up period(P < 0.05). The results indicate that FGS in MGN is associated with a
significantly poorer prognosis than MON without this lesion.
Idiopathic membranous glomerulonephritis (MGN) is an im-
portant cause of the nephrotic syndrome and renal failure in
adults [1—3]. The etiology of the disease is unknown. It's clinical
course is quite variable with about 15 to 50% of patients
developing chronic renal failure within 10 to 15 years of
diagnosis [1—7].
MGN may be associated with a number of other glomerular
lesions such as IgA nephropathy [8, 9], diabetic glomeruloscler-
osis [10, 11], hereditary nephritis [11], minimal change disease
[11], the glomerular tip lesion [12], and focal glomerulosclerosis
(FGS) [13, 14]. In a recent review of 120 biopsies with a
diagnosis of MGN, 27 were identified as having superimposed
FGS. Because the significance of this association is uncertain, a
detailed study of these 27 patients was conducted to determine
clinicopathologic characteristics of this group and compare
them to MGN patients without the FGS lesion.
Methods
Patient selection
One hundred and twenty biopsies with a diagnosis of MGN
(excluding cases of lupus membranous nephritis) according to
accepted pathological criteria [15], done between January 1,
1981 and December 31, 1989, and having a minimum of 10
viable glomeruli available for histologic examination, were
reviewed. In all cases electron microscopy (EM) and/or direct
immunofluorescence (IF) was done. From this group 27 patients
whose biopsies exhibited superimposed focal glomerulosclero-
sis were identified (MGN-FGS). None of the patients were
hepatitis B antigen-positive, had received penicillamine or gold
prior to the development of their disease or had an accompa-
nying systemic disorder.
From the remaining patients with MGN but without the FGS
lesion, a control group of 25 patients (MGN) generally matched
to the MGN-FGS group for age, sex and stage of glomerular
lesion was selected, as this allowed us to achieve a more
manageable size of control group and a relatively good degree
of demographic and glomerular pathologic similarity between
the two groups. The underlying assumption was that the chosen
control group was a relatively good approximation of the whole
cohort of MGN patients without FGS. None of the MGN-FGS
or MON patients in this study was hepatitis B antigen-positive
or had received gold or penicillamine prior to the development
of their disease.
Pathology
Renal biopsies were divided into three portions for histology,
direct immunofluorescence (IF) and electron microscopy (EM)
and processed as described previously [16]. For the purposes of
this project, the biopsies were evaluated in detail for the
number of glomeruli exhibiting FGS, the presence of visceral
epithelial cell changes characterized by cytoplasmic swelling,
vacuolation and protein droplets, number of intraglomerular
foam cells, glomerular cross-sectional area, extent of tubuloin-
terstitial disease in the form of tubular atrophy with interstitial
fibrosis, vascular changes such as hyalinosis and intimal scle-
rosis, and pathological stage. Focal glomerulosclerosis was
defined as a focal segmental lesion characterized by mesangial
matrix expansion (sclerosis) with capillary ioop collapse vari-
ably accompanied by adhesions of the affected segment to
Bowman's capsule, segmental hyalinosis, and reactive changes
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in adjacent visceral epithelial cells [17]. As these segmental
sclerotic lesions were associated with another glomerular lesion
they were considered to be secondary.
The degree of tubular atrophy and vascular intimal sclerosis
and/or hyalinosis was estimated semi-quantitatively on a scale
from 0 to 3 as follows:
a) Tubular atrophy. For no tubular atrophy, the score was 0.
A score of 0.5 was assigned for tubular atrophy involving up to
5% of the tubules. Tubular atrophy of 6 to 25%, 26 to 50% and
greater than 50% of tubules were given scores of 1, 2 and 3,
respectively.
b) Vascular intimal change. Scores of 0, 1, 2 or 3 were
assigned for no change, mild, moderate or marked intimal
sclerosis and/or hyalinosis, respectively.
The estimates were done independently by both authors and
there was good qualitative agreement between the two (Spear-
man rank correlation coefficient = 0.8 for tubular atrophy, 0.9
for vascular change).
Morphometry
For the measurement of glomerular cross-sectional area a
method similar to that of Fogo et al [18] was employed. Only
those biopsies that had been embedded in polyglycol meth-
acrylate for histology, had glomeruli sectioned through the
hilum or equator (for maximum circumference) and had a
minimum of six glomeruli for measurement were assessed. One
micron periodic acid-silver methenamine (PASM)-stained sec-
tions were used. The area delimited by Bowman's capsule was
measured with the aid of a digitizer and a morphometric
computer program (Bioquant II, R&M Biometrics, Nashville,
Tennessee, USA). Twenty MGN-FGS and 13 MGN biopsies
met the requirements and were evaluated.
Pathological stage
MGN was staged according to accepted ultrastructural crite-
ria [19] in all but one case which did not have tissue for EM (but
did have glomeruli for IF).
Clinical and laboratory data
The relevant clinical and laboratory data were obtained
directly from hospital charts or from physician's records. The
laboratory tests included in this study include serum creatinine
(Scr), serum albumin (SAIb), serum total cholesterol (STC),
serum triglyceride (STG), urinalysis, and 24-hour urinary pro-
tein excretion. These were done by standard hospital laboratory
methods.
Statistical analysis
Student's 1-test, the chi-square test and the Mann-Whitney U
test were utilized where appropriate. Life table analysis and log
rank testing were used to determine and compare cumulative
renal survival curves for both groups [20]. Renal survival times
were measured from the time of biopsy until either the time of
development of established renal failure or the time of the last
Sc1. determination in those not in established renal failure. For
the purposes of this study, established renal failure was defined
as a
 176 molIliter on two or more separate occasions at
least three months apart or for a minimum of six months. P <
0.05 was considered significant for all tests.
Results
Pathology
An average of 27 glorneruli per biopsy (range 12 to 130) in
MGN-FGS and 20 glomeruli per biopsy (range 10 to 42) in MGN
were examined. The glomerular histological, IF and EM
changes characteristic of MGN [16, 18] were observed in the
biopsies of both groups. Varying degrees of tubular atrophy
with interstitial fibrosis were observed in all but three MGN-
FGS biopsies and in 15 of 25 MGN biopsies. Focal interstitial
inflammation was noted in 21 of 27 MGN-FGS biopsies and in
6 of 25 MGN cases. Vascular lesions in the form of arterial
intimal fibrosis and/or arteriolar hyalinosis were noted in the
majority of biopsies.
In addition to the characteristic changes of MGN, the MGN-
FGS biopsies demonstrated the histological glomerular lesions
of FGS in an average of five glomeruli per biopsy (16% of viable
glomeruli; range I to 82% of viable glomeruli per biopsy; Fig.
1). In 21 of 27 cases (78%), the adjacent visceral epithelial cells
were hypertrophic and contained cytoplasmie protein droplets.
These epithelial changes were not observed in any of the MGN
biopsies. Hyaline deposits in sclerotic segments were noted in
17 (63%) of the MGN-FGS biopsies. Varying numbers of
intraglomerular foam cells (Fig. 1) were present in 14 (52%) of
the MGN-FGS cases. The foam cells were often located in
sclerotic segments, but in some instances were seen in glomer-
uli without FGS mostly within capillaries and on occasion
within the mesangium. In those glomeruli with foam cells, the
number of foam cells per glomerulus varied from 1 to 15. None
of the MGN biopsies demonstrated either intraglomerular hya-
line or foam cells. Occasional glomerular capillary thrombi
were noted in one MGN-FGS and five MGN biopsies. None of
the biopsies demonstrated diffuse interstitial edema or fibrosis.
Table 1 presents a comparison of MGN-FGS with MGN with
respect to a number of biopsy variables. The mean cross-
sectional glomerular area for the 20 MGN-FGS biopsies was
36,104 5519 .t2 and was significantly greater than that of the
13 MGN biopsies (31,017 7639 2; P 0.032, Student's
1-test). [A value for mean normal adult glomerular area in
methacrylate-embedded tissue was calculated to be 28,853
1461 p. This figure was obtained by dividing the value deter-
mined for paraffin-embedded kidney (15,800 800 2) [18] by
the square of Weibel's correction factor of 0.74 for linear
shrinkage in paraffin-embedded sections [21]]. No attempt was
made to stratify the glomerular cross-sectional area analysis
according to age and sex since a previous study failed to
demonstrate any correlation of glomerular volume with either
of these parameters in adults [21]. Tubular atrophy was signif-
icantly greater in MGN-FGS than in MGN (P < 0.01, Mann-
Whitney U test). Although vascular changes were more marked
in MGN-FGS than in MGN the difference was not significant (P
> 0.05, Mann-Whitney U test).
Clinical and laboratory
The relevant clinical and laboratory data for both groups at
the time of biopsy are presented in Table 2. Hypertension and
microscopic hematuria were significantly more common in the
MGN-FGS group (63% and 61%, respectively) than in the MGN
group (38% and 22%, respectively; P = 0.006 in both cases,
chi-square test). The 24-hour urinary protein excretion was
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Fig. 1. Membranous glomerulonephri:is with focal glomeruloscierosis. A. A relatively early sclerotic lesion with capillary loop collapse and foam
cell infiltration (arrowheads) is present in the segment at 9 o'clock (arrow). (Toluidine blue, x312). B. More advanced lesions are observed in this
glomerulus which contains several sclerotic segments (arrows). There is capillary loop collapse, increased mesangial matrix and adhesions to
Bowman's capsule. Foam cells (arrowhead) are present in the sclerotic segment at 4 o'clock. (Toluidine blue, x312).
Table 1. Comparison of selected biopsy findings in patients with
membranous glomerulonephritis and focal glomerulosclerosis (MGN-
FGS) with those in patients with membranous glomerulonephritis
(MGN) alone
Parameter MGN-FGS MON P value
Mean proportion of 10.6 10.1 7.4 9.7 0.245°
obselete glomeruli %
Mean glomerular cross- 36,104 5519 31,017 7639 0.032°
sectional area 2
SD
Mean index of tubular 1.46 0.85 0.58 0.61 <0.01"
atrophy si
Mean index of vascular 1.15 0.85 0.68 0.61 >0.05"
intimal changes SD
Stage of MGN % I 11.5 4 0.327c
II 65.4 68 0.847c
III 23.1 28 0.694c
a Student's t-test
b Mann-Whitney U test
Chi-square test
significantly higher in MGN-FGS (11.9 8.9 g) than in MON
(6.3 3.3 g; P = 0.004, Student's i-test). A higher proportion of
MGN-FGS patients presented with the nephrotic syndrome
than did the MON patients (92.6% vs. 72%, P 0.051,
chi-square test). There were no significant differences between
the groups with respect to mean age, male: female ratio, dura-
tion of disease prior to biopsy, mean Sr, mean SAIb, mean STC,
and mean STG.
Because some antihypertensive drugs may affect glomerular
hemodynamics and possibly reduce urinary protein excretion
[22, 23], the MON patients on antihypertensive drugs at the
time of biopsy were assessed with respect to urinary protein
excretion. The nine MGN patients on antihypertensives had a
Table 2. Clinical and laboratory findings in patients with
membranous glomerulonephritis and focal glomeruloscierosis (MGN-
FOS) and with membranous glomerulonephritis alone (MGN)
Parameter MGN-FGS MGN P
Mean age years SD 58.6 13.2 56.6 14.0 0.789°
Male:female ratio 17:10 17:8
Mean duration of disease 5.3 5.0 9.9 10.9 0.085°
prior to biopsy months
SD
Patients with nephrotic 92.6 72 0.051"
syndrome %
Patients with 63 37.5 06b
hypertension %
Patients with 61 22 0.0O6'
microhematuria %
Patients with 31 20 0.388"
Sr >124 mol/liter, %
Mean Sr smol/liter SD 133 75 109 47 0.118°
Mean serum albumin 22.0 5.2 24.1 7.6 0.272°
giliter SD
Mean serum TC mmol/ 11.2 4.2 9.1 2.5 0.090°
liter SD
Mean serum TG mmol/ 5.2 4.5 3.2 2.1 0.378°
liter SD
Mean urinary protein g/24 11.9 8.8 6.3 3.3 0.004°hrs SD
Abreviations are: Scr, serum creatinine; TC, total cholesterol; TG,
triglyceride.
a Student's (-testb Chi-square test
mean 24-hour urinary protein excretion of 6.4 2.5 g, which
was very close to the excretion rate of the entire MGN group
(6.3 3.3 g/24 hours; P > 0.05, Student's t-test). None of the
MON patients was on a protein-restricted diet.
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Table 3. Follow-up clinical findings in patients with membranous
glomerulonephritis and focal glomerulosclerosis (MGN-FGS) and
with membranous glomerulonephritis alone (MGN)
Parameter MGN-FGS MGN P
Range of post-biopsy follow-up 2—96 3—95
interval months
Mean post-biopsy follow-up 32.2 29.4 41,6 27.3 0.256a
interval months
No. of patients lost to follow-up % 2 (7.4) 3 (12) 0.583k'
No. of patients with established 12 (48) 3 (13) 0008b
renal failurec %
No. of patients who died % 6 (24) 3 (14) 0.379"
No. of patients on dialysis % 4 (16) 1 (4.5) 0212b
No. of patients in remission" % 5 (20) 7 (33) 0316b
Renal survival ratee at 24 months 0.61 0,93 O.O27
60 months 0.48 0.88 0.0211'
a Student's 1-test
Chi-square test
C Established renal failure is defined as having a serum creatinine
176 mol/liter on at least 2 separate occasions at least 3 months apartd Remission is defined as having a normal serum creatinine and a
24-hour urinary protein <1.0 g
e Renal survival is defined as not having established renal failure.
Patients with established renal failure at biopsy were considered to have
developed the renal failure at 3 months post-biopsy for the purposes of
analysis.
Log rank test
compared to the entire cohort of patients with MGN (without
FGS) with respect to a number of clinical and laboratory
parameters at the time of biopsy. The two groups were clini-
cally and pathologically equivalent in that there were no signif-
icant differences between the two with respect to age,
male: female ratio, proportion with the nephrotic syndrome,
percent with hypertension, mean Se,., mean SAIb, mean STC,
mean STG, mean 24-hour urinary protein excretion, proportion
of patients with advanced glomerular disease (stage III), the
extent of tubulointerstitial disease or the degree of vascular
disease.
The relevant follow-up data are presented in Table 3. Eigh-
teen patients from each group were treated with varying doses
of prednisone with or without an immunosuppressive (pred-
nisone alone: N = 10 for both groups; prednisone + immuno-
suppressive: N = 8 for both groups) for variable periods of
time. The mean interval from biopsy to last follow-up visit,
death or time of development of established renal failure was
32.2 29.4 months (range 2 to 96 months) for the MGN-FGS
group and 41.6 27.3 months (range 3 to 95 months) for
MGN, the difference being not significant. A significantly higher
proportion (48%) of MGN-FGS patients developed established
renal failure than did the MGN group (13%; P = 0.008,
chi-square test). Six (24%) MGN-FGS (5 males, 1 female) and 3
(14%) MGN (2 males, 1 female) patients died during the period
of the study (P = 0.379, chi-square test). The causes of death
were acute myocardial infarction (2 males), carcinomatosis (1
female), carcinoma of the prostate with metastases (1 male),
congestive cardiomyopathy (1 male), cerebrovascular accident
(1 female), pneumonia with septicemia (1 male), and unknown
(2 males).
The cumulative renal survival (not being in established renal
failure) curves for the MGN-FGS and MGN groups are de-
picted in Figure 2. For the purpose of analysis, patients with
renal failure at biopsy were considered to have developed it at
three months post-biopsy. The 24- and 60-month cumulative
survival rates were 0.61 and 0.48, respectively, for MGN-FGS
and 0.93 and 0.88, respectively, for MGN. The differences
between the two groups for both times were significant (P =
0.027 at 24 months, P = 0.021 at 60 months, log rank test). The
difference in the cumulative renal survival rates over the entire
follow-up period between the two groups was also significant (P
= 0.026, log rank test). It should be noted that the course of the
disease in the MGN group was very similar to that of a
published summary of outcome of a large number of patients
with MON compilated from numerous reports [24].
Discussion
The association of FGS with MON has been the subject of
occasional reports in the past [13, 14, 25]. While two previous
studies have suggested a deleterious effect of FGS on the course
of MON [14, 25], the results of another did not show this [13].
However, this latter report included only two patients [13]. The
results of the present investigation indicate that the presence of
FGS in MGN is associated with significant worsening of the
prognosis in those patients whose biopsies demonstrate FGS
with MGN. The deleterious effect of FGS has also been
observed in children with hepatitis B surface antigen-associated
MGN [26].
A number of prognostic factors, many of which are contro-
versial, have been identified in MGN. These include age [1, 2,
4, 5], sex [2, 27], extent of tubulointerstitial and vascular
disease [5, 7, 28], severity of proteinuria [1, 2, 29], renal
function at the time of diagnosis [1, 2, 4, 19, 301, duration of
disease prior to biopsy [28, 30], hypertension [4, 19], HLA type
[28, 311, and stage of glomerular disease [1, 4, 19, 28]. Although
the present study was not designed to specifically test the
validity of the above factors, it is of interest to note that the
patients with MGN-FGS had significantly more tubulointersti-
tial disease, a higher proportion of patients with hypertension
and the nephrotic syndrome, and a greater degree of proteinuria
than did the control patients.
The effect of specific therapy involving steroids with or
without an immunosuppressive is controversial [27]. Some
reports suggest that steroids with or without an immunosup-
pressive improve the long-term outcome of MGN [32, 33], while
other studies indicate that steroid therapy has no benefit [34,
35]. Although no attempt was made to control a priori for this
factor in the present investigation, both groups were very
similar with respect to the number of patients who received
either steroids alone or steroids with an immunosuppressive,
suggesting that specific therapy cannot account for the differ-
ence in outcomes between the MGN-FGS and the MON
groups. However, information on doses and length of treatment
of the various chemotherapeutic agents involved was incom-
plete and thus the possibility of a treatment effect cannot be
completely excluded.
The visceral epithelial changes described in many of the
MGN-FGS patients were not observed in any of the MON
biopsies. These epithelial changes, while commonly present in
FGS [17], are nonspecific and may be seen in other forms of
glomerular disease, both human and experimental, in which
there is substantial proteinuria and/or other processes that





hypertension [36—39]. The prevalence of both marked protein-
uria and hypertension in the MGN-FGS group may thus ac-
count for the great difference in incidence of visceral epithelial
changes between the two groups in the present study.
Tubulointerstitial lesions were significantly more prevalent in
the MGN-FGS group than in the MGN biopsies. The pathogen-
esis of the lesion is uncertain, but may be related to the degree
and duration of proteinuria as has been shown experimentally
[40—43]. This may account for the greater degree of tubuloin-
terstitial disease in the MGN-FGS patients as they had signifi-
cantly greater proteinuria than did the MGN group.
It has been stated that the glomerular tip (paratubal) lesion
(segmental sclerosis localized to the urinary role of the glomer-
ular tuft) is distinct and should not be considered as a form of
FGS [44, 45]. These lesions have been demonstrated in MGN
and were thought not to have an effect on that disease [12]. For
the purposes of the present study, the glomerular tip lesion was
considered a form of FGS and was observed in nine biopsies,
either as the sole type of segmental sclerosis in four cases, or
with segmental sclerosis in other glomerular locations in five
biopsies. With respect to the former four patients, two had
established renal failure at the time of diagnosis, one developed
renal failure eight months after biopsy and the fourth had
persistent nephrotic syndrome and normal renal function 24
months after biopsy. While not conclusive, these results sug-
gest that the glomerular tip lesion is a form of FGS in agreement
with other reports [46, 47], and may have a significant impact on
outcome in MGN.
The etiology and pathogenesis of FGS in MGN are uncertain.
A number of factors have been implicated in the pathogenesis of
FGS suggesting a multifactorial process analogous to athero-
sclerosis [17, 48]. The factors that have been shown experimen-
tally to play a role in the development of the FGS lesion include
hemodynamic ones such as systemic hypertension and glomer-
ular capillary hypertension, hyperfusion and hyperfiltration [49,
50], coagulation [51], hyperlipidemia [52, 53], monocytes [54—
56], mesangial dysfunction [57, 58], genetic factors [59], gb-
merular hypertrophy [60] and altered glomerular permeability
to macromolecules [43]. In keeping with this, the MGN-FGS
patients showed a significantly greater prevalence of hyperten-
sion and a greater degree of proteinuria than did the MGN
group. As well, mean glomerular cross-sectional area of the
MGN-FGS group was significantly greater than that of the
MGN one. Although it is tempting to speculate about the
pathogenetic significance of these factors in the development of
FGS in MGN, the design of our study does not allow us to draw
any conclusions in this area. However, inasmuch as hyperten-
sion and marked proteinuria are associated with progression of
MGN [1, 2, 4, 19, 29], measures such as the use of angiotensin
converting enzyme inhibitors, which have been shown to
reduce proteinuria [22, 23] in addition to lowering blood pres-
sure, may be worth considering in the management of MGN
patients with these clinical characteristics.
In conclusion, the results of this study indicate that the
development of secondary FGS in MGN is associated with a
significantly poorer prognosis compared to MGN alone. Be-
cause the segmental sclerotic lesion is associated with a number
of pathological and clinical factors that have been shown to
have deleterious effect on the course of MGN, additional
investigation of this phenomenon is required to assess whether
or not FGS is an independent prognostic factor in MGN.
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